Online inquiry

IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3382MR)

This product GTTS-WQ3382MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets Canlupfam CD52 gene. The antibody can be applied in Canine T-cell lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Caninized
RefSeq NM_001003240.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 403918
UniProt ID Q28896
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ3382MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14452MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ6437MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CT-P22
GTTS-WQ13441MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PRO95780
GTTS-WQ9819MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JS004
GTTS-WQ12218MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ14335MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG7414
GTTS-WQ9981MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA KD-247
GTTS-WQ1647MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACT-017
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW